- DKK547.10m
- DKK499.72m
- DKK40.29m
Brief: Bioporto Q1 Revenue DKK 9.4 Mln
Denmark's BioPorto Q1 revenue rises 23%, EBITDA loss narrows
Brief: BioPorto Q1 Adjusted EBITDA DKK -17.9 Million
Brief: Bioporto Adjusts FY 2026 Guidance Following Antibody Business Divestment
Brief: Bioporto A/S Says Co Submits FDA Pre-Submission Package For U.S. Adult Urine Ngal Program
Brief: Bioporto A/S Appoints Chief Financial Officer
Denmark's BioPorto Q4 revenue rises on NGAL sales
Brief: BioPorto Q4 Adjusted EBITDA DKK 13.7 Million
Brief: Bioporto A/S Says Niels Høy Nielsen Has Resigned As CFO Of Bioporto
Brief: Bioporto Gross Proceeds From Issue Will Amount To About DKK 43 Mln
Brief: BioPorto Q3 EBIT DKK -23 Million
Brief: BioPorto Completes Private Placement
Brief: BioPorto Q3 Adjusted EBITDA DKK -16.8 Million
Brief: Bioporto Expects 2025 Adj EBITDA Loss Of DKK 75-80 Mln
Brief: Bioporto Appoints Carsten Buhl As New CEO
Brief: Bioporto Keeps Full-Year Guidance Unchanged
Brief: Bioporto Initiates Private Placement Of DKK 33.5 Mln
Brief: BioPorto Outlook FY Adjusted EBITDA DKK -85 To -75 Million
Brief: Bioporto A/S Says Board To Appoint Jens Due Olsen As Chair, Along With Updates On Other Candidates